CTMX
CytomX Therapeutics Inc
Halal Rating :
Last Price
$0.84
Last updated:
Market Cap
-
7D Change
-4.96%
1 Year Change
-48.26%
Company Overview
Industries
Exchange
Next Earnings Date
CytomX Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel antibody therapeutics for the treatment of cancer. The company's proprietary Probody® technology platform is designed to make antibody therapeutics safer and more effective by ensuring they remain inactive until they reach their intended tumor targets.
The company generates revenue primarily through research and development collaborations with other pharmaceutical companies, milestone payments, and licensing agreements.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $33.43m | $29.32m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $25.11m | $33.57m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $41.46m | $29.81m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate CytomX Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.